Payment overview · 2025
General Payments
$525.82
25 reported records · 9 companies
Healthcare provider profile · identity verified
Michael Anthony Berk, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1700802014
Verified facts
What the public records show
CMS Open Payments records show Michael Anthony Berk, MD received $525.82 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 394 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $117.22 | 22.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $91.71 | 17.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.28 | 14.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.25 | 14.5% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $50.97 | 9.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.34 | 8.6% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $29.55 | 5.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.69 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.81 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.82 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $117.22 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $117.22 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $91.71 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $77.28 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.25 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $50.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 251 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 214 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 394 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
251 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
394 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
184 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 655 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 618 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 576 | 161 |
| Lisinopril | Lisinopril | 473 | 123 |
| Mounjaro | Tirzepatide | 394 | 66 |
| Omeprazole | Omeprazole | 375 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 87 |
| Simvastatin | Simvastatin | 281 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 70 |
| Losartan Potassium | Losartan Potassium | 272 | 77 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 254 | 85 |
| Farxiga | Dapagliflozin Propanediol | 251 | 53 |
| Metformin Hcl | Metformin Hcl | 245 | 70 |
| Tramadol Hcl | Tramadol Hcl | 243 | 80 |
| Alprazolam | Alprazolam | 242 | 77 |
| Valsartan | Valsartan | 236 | 66 |
| Jardiance | Empagliflozin | 214 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 212 | 46 |
| Gabapentin | Gabapentin | 210 | 56 |
| Trulicity | Dulaglutide | 184 | 40 |
| Glimepiride | Glimepiride | 181 | 53 |
| Allopurinol | Allopurinol | 177 | 40 |
| Furosemide | Furosemide | 174 | 47 |
| Metformin Hcl Er | Metformin Hcl | 161 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 46 |
| Ozempic | Semaglutide | 147 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 43 |
| Januvia | Sitagliptin Phosphate | 140 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 41 |
| Potassium Chloride | Potassium Chloride | 134 | 33 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 124 | 46 |
| Humalog Kwikpen U-100 | Insulin Lispro | 121 | 45 |
| Ezetimibe | Ezetimibe | 120 | 28 |
| Eliquis | Apixaban | 117 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 111 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 103 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 35 |
| Azithromycin | Azithromycin | 102 | 83 |
| Sertraline Hcl | Sertraline Hcl | 101 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 26 |
| Meloxicam | Meloxicam | 96 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 25 |
| Lorazepam | Lorazepam | 94 | 23 |
| Synthroid | Levothyroxine Sodium | 94 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 25 |
| Atenolol | Atenolol | 89 | 24 |
| Irbesartan | Irbesartan | 88 | 25 |
| Carvedilol | Carvedilol | 86 | 24 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 85 | 28 |
| Trazodone Hcl | Trazodone Hcl | 83 | 27 |
| Novolog Flexpen | Insulin Aspart | 82 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | 14 |
| Tradjenta | Linagliptin | 77 | 14 |
| Clonazepam | Clonazepam | 76 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 24 |
| Repatha Sureclick | Evolocumab | 68 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 18 |
| Clonidine Hcl | Clonidine Hcl | 62 | 12 |
| Famotidine | Famotidine | 62 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 62 | 13 |
| Glipizide Er | Glipizide | 61 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 20 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Glipizide | Glipizide | 55 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 15 |
| Pregabalin | Pregabalin | 54 | 21 |
| Diazepam | Diazepam | 53 | 13 |
| Humalog | Insulin Lispro | 53 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 38 |
| Finasteride | Finasteride | 52 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 16 |
| Novolog | Insulin Aspart | 52 | 19 |
| Ondansetron Odt | Ondansetron | 52 | 21 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Lovastatin | Lovastatin | 49 | 14 |
| Spironolactone | Spironolactone | 49 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Linzess | Linaclotide | 46 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 45 | 14 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 40 | 16 |
| Baclofen | Baclofen | 39 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 36 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 36 | suppressed |
| Repatha Syringe | Evolocumab | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Nadolol | Nadolol | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 17 |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Praluent Pen | Alirocumab | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 26 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 13 |
| Admelog | Insulin Lispro | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Xyosted | Testosterone Enanthate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.82 · 25 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, REPATHA, Rybelsus, TZIELD, Tymlos, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error